Nothing Special   »   [go: up one dir, main page]

Britton, 2019 - Google Patents

Generation and functional comparison of anti-CD20 chimeric antigen receptors

Britton, 2019

View PDF
Document ID
10720692518758217183
Author
Britton R
Publication year

External Links

Snippet

Chimeric antigen receptor (CAR) T-cell therapy has proven effective, particularly in targeting relapsed, refractory haematological malignancies. However, optimal CAR design is not fully understood. It is known that the antigen epitope position, affinity of interaction and the length …
Continue reading at eprints.soton.ac.uk (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
Yilmaz et al. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
US20230340113A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
TWI823829B (en) CHIMERIC ANTIGEN RECEPTORS (CARs) TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOF
US20210246423A1 (en) Methods for improving the efficacy and expansion of immune cells
Guillerey et al. Targeting natural killer cells in cancer immunotherapy
KR102697827B1 (en) Modified monocytes/macrophages expressing chimeric antigen receptors and uses thereof
US20190175651A1 (en) Immortalized car-t cells genetically modified to elminate t-cell receptor and beta 2-microglobulin expression
JP2022091750A (en) Cell-based neoantigen vaccines and uses thereof
EP3641768A1 (en) Chimeric antigen receptors (cars), compositions and methods thereof
JP2018522907A (en) Cells for immunotherapy engineered to target the CD38 antigen and to inactivate the CD38 gene
Nemoto et al. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1
US20220267425A1 (en) Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors
JP2022530773A (en) Antigen-specific CD19 targeted CAR-T cells
US20240252641A1 (en) Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
CN114929341A (en) Chimeric antigen receptor for the treatment of myeloid malignancies
Britton Generation and functional comparison of anti-CD20 chimeric antigen receptors
US20240360236A1 (en) Methods for targeted immunotherapy of acute myeloid leukemia (aml)
Heckel Characterisation of novel human CD27-specific monoclonal antibodies for cancer therapy
TWI859112B (en) Methods for improving the efficacy and expansion of immune cells
Paluch Manipulating immune checkpoint signalling pathways with antibodies
Dadas Development and activity of a single chain CD70 dimer-of-trimer and its potential as a therapeutic immunostimulatory agent
Brossart et al. OPEN ACCESS EDITED AND REVIEWED BY
Özkazanç Ünsal Development of a novel in vitro screening method using genetically modified NK-92 cells against various tumor cells
AU2024227595A1 (en) Methods for improving the efficacy and expansion of immune cells
Umana Development of TCR-engineered iNKT cells for Cancer Immunotherapy